Literature DB >> 15031179

Retinal toxicity of intravitreal tenecteplase in the rabbit.

S A Rowley1, S Vijayasekaran, P K Yu, I L McAllister, D-Yi Yu.   

Abstract

AIM: To investigate the retinal toxicity of intravitreal injection of a novel fibrinolytic tenecteplase in rabbit eyes.
METHODS: Tenecteplase (25-350 micro g in 0.1 ml BSS) was injected into the vitreous cavity of normal rabbit eyes. Control (fellow) eyes received 0.1 ml of BSS. One day, 1 week, and 2 months post-injection, the eyes were examined by slit lamp biomicroscopy, indirect ophthalmoscopy, and electroretinography, and then harvested for histopathological examination.
RESULTS: No evidence of retinal toxicity was seen with tenecteplase doses up to and including 50 micro g. At a dose of 150 micro g ophthalmoscopy was normal, but histology showed mild retinal damage in the inner nuclear layer and electroretinography showed a temporary reduction in B-wave amplitude. At doses of 200 micro g and above, there was evidence of retinal toxicity on electroretinography, ophthalmoscopy, and histology. Ophthalmoscopic findings included vitreal fibrosis, retinal necrosis and tractional retinal detachment and light microscopy revealed necrosis of retinal pigment epithelium and other retinal layers. Damage was centred around the injection site but was more widespread with the higher doses.
CONCLUSION: A dose of 50 micro g tenecteplase appears safe for intravitreal injection in the rabbit. Tenecteplase could have potential applications in the treatment of submacular haemorrhage and retinal vein occlusion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15031179      PMCID: PMC1772065          DOI: 10.1136/bjo.2003.027466

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  17 in total

1.  Retinal toxicity of recombinant tissue plasminogen activator in the rabbit.

Authors:  M W Johnson; K R Olsen; E Hernandez; W D Irvine; R N Johnson
Journal:  Arch Ophthalmol       Date:  1990-02

2.  Tissue plasminogen activator for postvitrectomy fibrin formation.

Authors:  G J Jaffe; G W Abrams; G A Williams; D P Han
Journal:  Ophthalmology       Date:  1990-02       Impact factor: 12.079

3.  Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions.

Authors:  L O Hattenbach; C Klais; F H Koch; H O Gümbel
Journal:  Ophthalmology       Date:  2001-08       Impact factor: 12.079

Review 4.  Issues in the assessment of the safety and efficacy of tenecteplase (TNK-tPA).

Authors:  C M Gibson; S J Marble
Journal:  Clin Cardiol       Date:  2001-09       Impact factor: 2.882

5.  Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion.

Authors:  J N Weiss; L A Bynoe
Journal:  Ophthalmology       Date:  2001-12       Impact factor: 12.079

6.  Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration.

Authors:  C L Haupert; B W McCuen; G J Jaffe; E R Steuer; T A Cox; C A Toth; S Fekrat; E A Postel
Journal:  Am J Ophthalmol       Date:  2001-02       Impact factor: 5.258

Review 7.  Tenecteplase: a review.

Authors:  L Davydov; J W Cheng
Journal:  Clin Ther       Date:  2001-07       Impact factor: 3.393

8.  Retinal toxicity of commercial intravitreal tissue plasminogen activator solution in cat eyes.

Authors:  C J Hrach; M W Johnson; A S Hassan; B Lei; P A Sieving; V M Elner
Journal:  Arch Ophthalmol       Date:  2000-05

9.  Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.

Authors:  F Van De Werf; J Adgey; D Ardissino; P W Armstrong; P Aylward; G Barbash; A Betriu; A S Binbrek; R Califf; R Diaz; R Fanebust; K Fox; C Granger; J Heikkilä; S Husted; P Jansky; A Langer; E Lupi; A Maseri; J Meyer; J Mlczoch; D Mocceti; D Myburgh; A Oto; E Paolasso; K Pehrsson; R Seabra-Gomes; L Soares-Piegas; D Sùgrue; M Tendera; E Topol; P Toutouzas; A Vahanian; F Verheugt; L Wallentin; H White
Journal:  Lancet       Date:  1999-08-28       Impact factor: 79.321

10.  Quantitative effect of intravitreally injected tissue plasminogen activator and gas on subretinal hemorrhage.

Authors:  L Hesse; B Schroeder; G Heller; P Kroll
Journal:  Retina       Date:  2000       Impact factor: 4.256

View more
  6 in total

1.  Management of Acute Submacular Hemorrhage with Intravitreal Injection of Tenecteplase, Anti-vascular Endothelial Growth Factor and Gas.

Authors:  Jung Pil Lee; Jun Sang Park; Oh Woong Kwon; Yong Sung You; Soon Hyun Kim
Journal:  Korean J Ophthalmol       Date:  2016-05-18

2.  The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator.

Authors:  Matthias Lüke; Kai Januschowski; Max Warga; Julia Beutel; Martin Leitritz; Faik Gelisken; Salvatore Grisanti; Toni Schneider; Christoph Lüke; Karl Ulrich Bartz-Schmidt; Peter Szurman
Journal:  Br J Ophthalmol       Date:  2007-03-23       Impact factor: 4.638

3.  Retinal safety of intravitreal rtPA in healthy rats and under excitotoxic conditions.

Authors:  Alejandra Daruich; Jérôme Parcq; Kimberley Delaunay; Marie-Christine Naud; Quentin Le Rouzic; Emilie Picard; Patricia Crisanti; Denis Vivien; Marianne Berdugo; Francine Behar-Cohen
Journal:  Mol Vis       Date:  2016-11-10       Impact factor: 2.367

4.  Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions.

Authors:  Steven A Giannos; Edward R Kraft; Zhen-Yang Zhao; Kevin H Merkley; Jiyang Cai
Journal:  Pharm Res       Date:  2018-02-28       Impact factor: 4.200

5.  Surgical management of submacular hemorrhage due to n-AMD: a comparison of three surgical methods.

Authors:  Carsten Grohmann; Spyridon Dimopoulos; Karl Ulrich Bartz-Schmidt; Philipp Schindler; Toam Katz; Martin S Spitzer; Christos Skevas
Journal:  Int J Retina Vitreous       Date:  2020-07-02

6.  Gene expression profile analysis of the rabbit retinal vein occlusion model.

Authors:  Takuma Neo; Makoto Gozawa; Yoshihiro Takamura; Masaru Inatani; Masaya Oki
Journal:  PLoS One       Date:  2020-07-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.